Anyone affected by internal bleeding after taking Pradaxa is encouraged to speak with a lawyer about their legal options.
Chicago, IL (PRWEB) May 08, 2013
The medication resource center DrugRisks.com is announcing new information on the site for patients taking the blood thinner Pradaxa. The maker of the drug recently updated label warnings to include the risk of a blood platelet disorder*.
DrugRisks was created to improve the safety of patients taking popular prescription drugs by providing the latest warnings, recalls, studies and legal news. Visitors can see if others are experiencing similar side effects and decide if they need legal advice.
Health experts have disagreed over whether Pradaxa has higher risks of internal bleeding than traditional anticoagulants. The FDA has stated the drug is as safe as warfarin**. However, the Institute for Safe Medication Practices recently ranked drugs like Pradaxa among the most dangerous, and warned that Pradaxa bleeding may be 5 times as likely to result in death than bleeding from warfarin or Coumadin***.
The resource center has also added a study from the University of Illinois at Chicago suggesting the data used by the FDA may be flawed, and the risk for Pradaxa bleeding may be higher than expected****.
Now, DrugRisks has learned that the maker of the drug, Boehringer Ingelheim, recently added a new Pradaxa side effect warning to the label advising of the risk of thrombocytopenia, a drop in blood platelets that can result in Pradaxa internal bleeding*.
With a growing number of patients filing a Pradaxa lawsuit alleging internal bleeding, cases have been consolidated to a special federal court in Illinois. The case is formally known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.
Anyone affected by internal bleeding after taking Pradaxa is encouraged to speak with a lawyer about their legal options. Due to the specialized nature of federal drug injury cases, DrugRisks only recommends lawyers who have already handled Pradaxa lawsuits.
*Boehringer Ingelheim, 4/30/13; us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2013/04-30-13-boehringer-ingelheim-pharmaceuticals-prescribing-information-pradaxa-dabigatran-etexilate-mesylate.html
**FDA 11/2/12; http://www.fda.gov/Drugs/DrugSafety/ucm326580.htm
***Institute for Safe Medication Practices, 1/9/13; ismp.org/quarterwatch/pdfs/2012Q2.pdf
****New England Journal of Medicine, 4/4/13; nejm.org/doi/full/10.1056/NEJMp1302834